Consolidated Revenue Growth
Revenue for Q1 2026 was $12.2 million, up ~5.2% year-over-year, driven by retail strength in Ohio which more than offset weakness in Arizona.
Material Gross Profit and Margin Expansion
Gross profit more than doubled to $5.5 million with a gross margin of 45.4% in Q1 2026 versus $2.3 million (19.7%) in the prior-year period; gross profit before fair value adjustments was $4.4 million (35.8% margin) versus $4.0 million (34.0%) prior-year.
Strong Adjusted EBITDA and Margin Improvement
Adjusted EBITDA was $3.6 million with a 29.3% margin in Q1 2026, improving from $2.1 million (15% margin) in Q4 2025 and comparable to prior-year Q1 adjusted EBITDA ($3.4M, ~29.6%).
Net Loss Narrowed Significantly
Net loss narrowed to $0.9 million in Q1 2026 from a $3.3 million loss in Q1 2025—an improvement of approximately $2.4 million, or ~73%.
Positive Operating Cash Flow Despite Headwinds
Cash from operations was $1.6 million in Q1 2026 (cash flow margin 13%), and ending cash increased to ~$5.5 million from ~$5.1 million at year-end 2025, demonstrating ongoing cash generation while executing strategic transitions.
Ohio: Primary Growth Driver and Retail Expansion
Ohio revenue increased 34% year-over-year to $8.2 million; statewide Ohio sales (2-month data through Feb) increased >20% YoY. Company expects to open the 6th dispensary (Fairfield) in Q2 2026, 7th in Columbus later in 2026, and advance an 8th license into early 2027, with emphasis on drive-thru capability.
Cultivation Yield Improvements and Sourcing Cost Advantage
Ohio cultivation yields improved almost 15% in Q1 2026 with further strong improvement expected in Q2; company expects to opportunistically source wholesale product at ~ $400–$500 per pound (and occasionally < $400), versus previous internal Arizona cultivation all-in costs of ~$800–$900 per pound.
Strategic De-risking of Arizona Cultivation
Management executed a decisive exit from the Eloy cultivation facility (final harvest in early May) expecting completion of the cultivation exit by end of Q2 2026, refocusing Arizona on two Phoenix Metro dispensaries and light manufacturing to reduce operating costs and improve margin/cash flow profile.